secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0000320017-25-000010
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lisata Therapeutics reports 2024 net loss $20M, cash $31.2M; promising Phase 2b pancreatic cancer data
--------------------------------------------------------------------------------

- Revenue $1.0M from Kuva license (vs $0 in 2023); operating expenses down 8.9% to $23.4M.
- Net loss $20.0M vs $20.8M in 2023; cash, equivalents & securities $31.2M; runway into Q2 2026.
- Phase 2b ASCEND (mPDAC) showed positive OS trend; four complete responses in certepetide arm, none in placebo.
- BOLSTER (cholangiocarcinoma) first-line enrollment complete; topline data expected mid-2025.
- iLSTA (PDAC+immunotherapy) 27 of 30 enrolled; enrollment completion H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000032001725000010/0000320017-25-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000032001725000010/clbs-20250227.htm
  HTML page:      https://secwatch.observer/filing/0000320017-25-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer